September 17, 2015 - An elevated infant death rate may be linked to mourning experienced by women in the months before they become pregnant, reports a study in Psychosomatic Medicine: Journal of Biobehavioral Medicine, the official journal of the American Psychosomatic Society. The journal is published by Wolters Kluwer.
"Our findings suggest that the six-month period prior to pregnancy may be a sensitive developmental period with implications for early offspring mortality," according to the new research, led by Quetzal A. Class, PhD. In contrast, maternal bereavement during pregnancy doesn't affect the infant mortality rate. The study was performed when Dr. Class was a doctoral student at Indiana University; she is now a postdoctoral researcher at the University of Chicago.
New Evidence Linking Bereavement around Conception to Infant Mortality
Using a Danish nationwide birth registry, the researchers analyzed data from all women who gave birth in Denmark between 1979 and 2009. Infant and child mortality rates were compared for women with and without "maternal bereavement"--defined as the death of a parent, sibling, or previously born child--in the months before conception or during pregnancy.
The analysis included data on nearly 1.9 million singleton births. Overall mortality rates were 0.004 percent during the first month of life, 0.002 percent between one month and one year, and 0.001 percent between one and five years.
The results showed increased mortality for infants born to mothers who experienced the death of a family member in the months before conception. After adjustment for other factors, risk of infant death during the newborn period (before one month) was more than 80 percent higher for women with preconception bereavement.
For infant death between one month and one year, risk was about 50 percent higher for women with bereavement before conception. The associations were weakened--but still significant--after further adjustment for gestational age and birth weight.
The increases in infant mortality were significant only between zero and six months before conception. Preconception bereavement had no effect on the risk of child death between age one and five years. Bereavement during pregnancy was unrelated to infant or child mortality.
While rates of early child mortality are improving, information on the causes of these tragic events is needed to develop effective global prevention programs. One previous study has suggested that grieving around the time of conception might be a risk factor for infant mortality. Other studies suggest that general stressors experienced before conception may impact offspring health.
Adding to that evidence, the new study finds that maternal bereavement within six months before conception is linked to an increased infant mortality rate. While the absolute risks are very low--a small fraction of a percentage point--the relative increases in infant mortality risk may be substantial.
"Bereavement is a major life stressor from both a psychological and physiological perspective," Dr. Class and coauthors write. Grieving may lead to changes in the maternal stress system affecting offspring development--particularly during the vulnerable period of early organ development--or alter the mother's biological preparedness for pregnancy.
The researchers note some important limitations of their study--highlighting the need for replication, examination of the specificity and severity of preconception stressors associated with mortality, and exploration of the biological mechanisms functioning in the preconception period.
Meanwhile, the results add new evidence that maternal bereavement immediately before pregnancy may increase the risk for newborn and infant mortality. Dr. Class comments, "Overall, this study emphasizes that the preconception period should not be overlooked when it comes to promoting infant health."
Article: "Preconception Maternal Bereavement and Infant and Childhood Mortality: A Danish Population-Based Study." (doi: 10.1097/PSY.0000000000000229)
About Psychosomatic Medicine
Psychosomatic Medicine, Journal of Biobehavioral Medicine, founded in 1939, is the official peer-reviewed journal of the American Psychosomatic Society. It publishes experimental and clinical studies dealing with various aspects of the relationships among social, psychological, and behavioral factors and bodily processes in humans and animals. Psychosomatic Medicine, Journal of Biobehavioral Medicine is an international, interdisciplinary journal devoted to experimental and clinical investigation in behavioral biology, psychiatry, psychology, physiology, anthropology, and clinical medicine. The print journal is published nine times a year; most articles are published online ahead of print.
About the American Psychosomatic Society
The mission of the American Psychosomatic Society is to promote and advance the scientific understanding and multidisciplinary integration of biological, psychological, behavioral and social factors in human health and disease, and to foster the dissemination and application of this understanding in education and health care.
The American Psychosomatic Society is a worldwide community of scholars and clinicians dedicated to the scientific understanding of the interaction of mind, brain, body and social context in promoting health. The organization is devoted to biopsychosocial research and integrated clinical care, and to providing a forum via its website, Annual Meeting and journal, Psychosomatic Medicine, for sharing this research. Its members are from around the world, including specialists from all medical and health-related disciplines, the behavioral sciences, and the social sciences.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2014 annual revenues of €3.7 billion. The group serves customers in over 170 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on NYSE Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit http://www.